|
To enter a Simulation, please read the information below and click the acceptance button at the bottom of the page.
Recognition and Management of COPD
Cases Developed by Expert Faculty
Adam Friedlander, MD
National Jewish Health
Assistant Professor
University of Colorado Denver
Release Date
September 22, 2009
Term of Approval
September 22, 2009 through September 21, 2010
Requests for credit must be received no later than September 21, 2010.
Introduction
Chronic obstructive pulmonary disease (COPD) is a preventable and treatable disease with some significant extrapulmonary effects that may contribute to the severity in individual patients. Its pulmonary component is characterized by airflow limitation that is not fully reversible.
COPD is a leading cause of morbidity and mortality worldwide, and results in an economic and social burden that is both substantial and increasing. It is projected that COPD, which ranked sixth as the cause of death in 1990, will become the third leading cause of death worldwide by 2020. Recent estimates suggest that up to 12 million Americans have a diagnosis of COPD, and there may be up to an additional 12 million with unrecognized airflow obstruction.
Target Audience
This activity was developed for Family Physicians, Nurse Practitioners, and Physician Assistants who treat patients with COPD.
Learning Objectives
Following completion of this case simulation, participants should be able to:
- Recognize and appropriately manage an acute exacerbation of COPD.
- Recognize that spirometry is required to make a diagnosis of COPD, and is also used to stage the severity and as a guide for therapy.
- Manage stable COPD, including the indications for long-term oxygen therapy, pulmonary rehabilitation, inhaled long-acting bronchodilators, and inhaled corticosteroids.
- Know when to refer a patient with COPD to a pulmonologist for consideration of other treatment options, such as lung volume reduction surgery.
Accreditation Statement
National Jewish Health is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation Statement
National Jewish Health designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
This CME Activity is sponsored by National Jewish Health.
This program was made possible by educational grants from GlaxoSmithKline and Pfizer.
Disclosure Information Listed for CME Content Development and Approval Committee and Participating Program Faculty
In accordance with the Accreditation Council for Continuing Medical Education, National Jewish Health requires that all program faculty, content developers, CME approval committee, and medical writers in a position to control the content of this activity are expected to disclose any or not significant financial interest or other relationship with any proprietary entity producing health care goods or services, with the exemption of non-profit or governmental organizations and non-health care related companies. Our goal is to ensure that there is no compromise of the ethical relationship that exists between those in a position to control the content of the activity and those attending the activity and their respective professional duties.
Significant financial interest is defined as receiving, or in the past twelve months having received, a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received or expected.
All CME Educational Activities sponsored by National Jewish Health are reviewed by our faculty CME committee to ensure a balanced and evidence-based presentation. Any potential conflict of interest among program faculty has been identified and resolved according to ACCME guidelines.
Faculty Disclosures
In accordance with the Accreditation Council for Continuing Medical Education, National Jewish Health requires that all persons in a position to control the content of a CME activity, including the CME review committee disclose all significant financial interest with commercial interests.
Key
A - Advisory Board B - Board of Directors C- Consultant E- Employer
F - Founder I - Investigator O - Other SP- Speaker SH - Stockholder
David Beuther, MD
SP – AstraZeneca
Adam Friedlander, MD
Has no significant financial interest to report
Michael Schwartz, MD
I – Respironics
Disclaimer
The information provided during this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition.
Hardware/Software Requirements
The simulation requires Microsoft Internet Explorer 6.0 or higher (get IE) or Mozilla Firefox version 2.0 or higher (get Firefox). Certain activities may require additional software to view multimedia, presentation or printable versions of their content. There are no specific hardware requirements.
|
